Fetal and neonatal effects of maternal drug treatment for depression.
Depression has a female sex predilection with 2 to 3% of the pregnant women population presently requiring treatment with selective serotonin reuptake inhibitors (SSRI). Exposure to SSRIs in late gestation leads to clinical manifestations in as much as 30% of the neonates. These include neurobehavioral, respiratory, gastrointestinal, and somatic symptoms. Among the respiratory manifestations, persistent pulmonary hypertension syndrome is a newly recognized and concerning side effect of SSRI exposure in utero. This causal association has been reproduced in an animal model where fluoxetine administration to pregnant rats induces fetal pulmonary hypertension. The pharmacological effects of SSRI on the fetus and newborn, available treatment, and prevention strategies are discussed in this review.
Belik
Jaques
J
The Hospital for Sick Children, University of Toronto, Toronto, Ontario, CA. Jaques.Belik@SickKids.ca
D000818:Animals; D003863:Depression / Q000188:drug therapy*; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced; D005473:Fluoxetine / Q000009:adverse effects; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D009422:Nervous System Diseases / Q000139:chemically induced; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000523:psychology*; D051381:Rats; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors